Indexed performance (as at: 13.11.2026)
NAV: USD 135.76 (15.11.2026)
Rolling performance (13.11.2026)
| Bellevue Emerging Markets Healthcare | MSCI Emerging Markets Healthcare Index | |
| 12.11.2025 - 12.11.2026 | 4.56% | 4.50% |
| 12.11.2024 - 12.11.2025 | 15.98% | 15.08% |
| 12.11.2023 - 12.11.2024 | -12.38% | 4.64% |
| 12.11.2022 - 12.11.2023 | -1.22% | 1.87% |
Annualized performance (13.11.2026)
| Bellevue Emerging Markets Healthcare | MSCI Emerging Markets Healthcare Index | |
| 1 year | 4.56% | 4.50% |
| 3 years | 2.04% | 7.96% |
| 5 years | -6.20% | -2.94% |
| Since Inception p.a. | 1.02% | 1.55% |
Cumulative performance (13.11.2026)
| Bellevue Emerging Markets Healthcare | MSCI Emerging Markets Healthcare Index | |
| 1M | 3.44% | 3.79% |
| YTD | 11.63% | 10.40% |
| 1 year | 4.56% | 4.50% |
| 3 years | 6.26% | 25.83% |
| 5 years | -27.39% | -13.86% |
| Since Inception | 10.04% | 15.65% |
Annual performance
| Bellevue Emerging Markets Healthcare | MSCI Emerging Markets Healthcare Index | |
| 2025 | 14.41% | 12.22% |
| 2024 | -14.91% | -0.90% |
| 2023 | -8.24% | -1.29% |
| 2022 | -19.39% | -23.50% |
Facts & Key figures
Investment Focus
The fund’s aim is to achieve capital growth in the long term, is actively managed and invests in companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of emerging countries. Its investment universe consists of generics producers, Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | CACEIS BANK, LUXEMBOURG BRANCH |
| Fund Administrator | CACEIS BANK, LUXEMBOURG BRANCH |
| Auditor | PriceWaterhouseCoopers |
| Launch date | 31.05.2017 |
| Year end closing | 30. Jun |
| NAV Calculation | Daily "Forward Pricing" |
| Cut of time | 09:00 CET |
| Management Fee | 1.60% |
| Subscription Fee (max.) | 5.00% |
| ISIN number | LU1585228452 |
| Valor number | 36153232 |
| Bloomberg | BBAEMBU LX |
| WKN | A2DPAU |
Legal Information
| Legal form | Luxembourg UCITS V SICAV |
| SFDR category | Article 8 |
| Redemption period | Daily |
Key data (31.10.2026, base currency USD)
| Beta | 0.96 |
| Volatility | 18.93 |
| Tracking error | 7.52 |
| Active share | 15.14 |
| Correlation | 0.92 |
| Sharpe ratio | -0.09 |
| Information ratio | -0.73 |
| Jensen's alpha | -5.83 |
| No. of positions | 42 |
Portfolio
Top 10 positions
Market capitalization
Geographic breakdown
Breakdown by sector
Benefits & Risks
Benefits
- Access to defensive growth – emerging countries are facing aging populations and changing lifestyles.
- Development of healthcare infrastructure combined with a growing middle class is an additional growth driver.
- High growth potential of Emerging Markets.
- Attractive valuations compared with the projected medium to long-term growth.
- Bellevue Healthcare Team – top-performing pioneer in the management of healthcare portfolios in Emerging Markets.
Risks
- The fund actively invests in equities. Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
- Investing in Emerging Markets entails the additional risk of political and social instability.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The fund may invest in China A equities. This entails the risk of supervisory changes, volume caps and operating restrictions which may lead to a higher counterparty risk.
- The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
Review / Outlook
Emerging-market equities declined 8.0% in October, as a gain in India’s Nifty 50 (+3.0%) was outweighed by declines in South Korea’s KOSPI (-14.8%), Brazil’s Ibovespa (-14.2%), China’s CSI 300 (-7.6%) and Hong Kong’s Hang Seng Index (-5.2%).
Emerging-market healthcare stocks declined 5.3% in October, outperforming the broader market, as concerns over the sustainability of AI investment and heavy foreign selling weitghed on technology-heavy markets. The Bellevue Emerging Markets Healthcare Fund declined 5.6% during the month, slightly underperforming its benchmark.
Genmab (+64.3%), Laurus Labs (+22.8%), Celltrion (+9.6%), Samsung Biologics (+9.5%) and Divi’s (+6.4%) were the fund’s top contributors to absolute performance during the month. Genmab surged after two positive Phase III readouts: Rina-S reduced the risk of disease progression or death by 71% in ovarian cancer, and petosemtamab reduced the risk of death by 50% in head and neck cancer. Laurus Labs reported a 126% increase in second-quarter net profit and 33% rise in revenue, sending its shares to a record high. Celltrion and Samsung Biologics rose despite the sharp decline in the KOSPI, supported by strong third-quarter results and their relative stability compared with semiconductor stocks. Divi’s climbed to a record closing high.
Akeso (-25.0%), GenScript (-21.9%), WuXi Biologics (-20.6%), Innovent (-18.6%) and WuXi AppTec (-13.8%) were the fund’s largest detractors from absolute performance during the month. Akeso came under pressure after announcing a discounted share placement, which raised concerns over dilution. Chinese biotech and CDMO stocks sold off after their strong September rally. Contributing factors were renewed share sales by some shareholders of Chinese CDMOs and a proposed revision to China’s technology export catalogue covering certain biomedical technologies. Innovent fell with the sector despite third-quarter product revenue rising more than 40% year-on-year.
All performance data in USD/B shares.
Emerging markets are home to some of the world’s most dynamic growth economies and account for more than half of the global population. By 2050, Asian emerging economies are expected to generate over 50% of global economic output. As incomes rise, many of these economies are shifting from industrial-led growth toward service-driven models. A growing middle class is fueling demand for modern medicine, as health becomes an increasingly important priority. Significant investments in infrastructure, technology, and research to modernize healthcare systems, exbanding access to higher-quality care. At the same time, demographic shifts are adding to demand. In 25 years’ time, China alone is expected to have nearly 400 million people over the age of 65, creating a significant need for advanced healthcare services and medicines.
Beyond Asia, attractive investment opportunities are also emerging in Brazil’s rapidly expanding private healthcare market. As the public healthcare system continues to struggle with quality and long waiting times, many affluent Brazilians are increasingly turning to private providers for better services. One notable example of beneficiaries of this trend can be found in hospital chains, which are building vertically integrated ecosystems to capture sustainable long-term growth.
Dokumente
Show moreShow less
ESG
Legal Notices
These insights might interest you

I am happy to answer any questions you may have:
Senior Sales Germany
Alexander Jostes




